BrightMEM™ corneal allograft
On-demand training & resources
Training videos
Brightstar Therapeutics video library
Eversight Academy has curated this free on-demand training to help you best serve your patients. Let us help you seamlessly adopt BrightMEM for anterior keratoplasty.
BrightMEM™
BrightMEM by Brightstar Therapeutics is a durable, acellular Descemet’s membrane with proliferative proteins. It forms a new foundation for the ocular surface, protecting the stroma from degradation, promoting regeneration of the corneal epithelium and optimizing limbal stem cell growth.
BrightMEM offers novel treatment for limbal stem cell deficiency (LSCD) and complex ocular surface disease (OSD). Patients living with these complex disease states often present with comorbidities, suffer poor vision and experience chronic eye pain and discomfort.
BrightMEM anterior keratoplasty (DMAK) is a simple on-lay procedure utilizing the decellularized corneal graft. The optically clear graft helps form a new foundation for the ocular surface while also reducing pain.
Preclinical data show limbal stem cell and epithelium support and protection from stromal melting. Early clinical results demonstrate re-epithelization without any serious tissue-related adverse reactions.
Resources
Surgical pearls
Case selection, graft prep, trephination, eye prep, securing the graft, post-op management & complications
Case report
Use of decellularized descemet membrane anterior keratoplasty to facilitate epithelialization of pediatric penetrating keratoplasty for total sclerocornea | Radwa Elsharawi, MD, MSc, et. al.
Case report
Use of BrightMEM corneal allograft in partial limbal stem cell deficiency (LSCD) | Joshua Hou, MD
White paper
Ocular surface reconstruction with BrightMEM corneal allografts: A foundation for durable epithelial regeneration | Joshua Hou, MD
White paper
BrightMEM corneal allograft: A vital tool for ocular surface challenges | Joshua Hou, MD
Information sheet
For surgery centers & hospitals